NIH-PA Author Manuscript

6"-Thioether tobramycin analogues: Towards selective targeting of bacterial membranes

Ido M. Herzog, **Keith D. Green**, **Yifat Berkov-Zrihen**, **Mark Feldman**, **Roee R. Vidavski**, **Anat Eldar-Boock**, **Ronit Satchi-Fainaro**, **Avigdor Eldar**, **Sylvie Garneau-Tsodikova**, and **Micha Fridman**

Keywords

Decades of widespread clinical use of the bacterial ribosome A-site targeting aminoglycosides (AGs) enhanced the evolution of resistance to these antibiotics and reduced their clinical efficacy.[1] Three modes of action lead to bacterial resistance to AGs: reduction in the intracellular concentration of the antibiotics by efflux pump proteins or through reduced membrane permeability; structural modifications of the 16S ribosomal RNA leading to reduced target affinity; and deactivation by AG-modifying enzymes (AMEs).[1c, 2] AMEs are divided into three families: AG nucleotidyltransferases (ANTs), AG phosphotransferases (APHs), and AG acetyltransferases (AACs).[1b, 3]

In many cases, AG-resistant bacteria have evolved combinations of resistance mechanisms, a fact that greatly increases the challenge of regaining their clinical efficacy through semi-synthetic modifications. In recent years, several studies demonstrated the potential of exploiting AGs for the development of cationic amphiphilic antimicrobial agents by converting part or all of their pseudo-oligosaccharide alcohols into alkyl or aryl ethers.[4] Some of these amphiphilic analogues demonstrated improved activities against several bacterial strains with resistance to the parent AG antibiotics. In addition to AG-based amphiphiles, several families of cationic amphiphiles including cationic steroids (ceragenins)[5] as well as cationic antimicrobial peptides and peptido-mimetics[6] have been developed and were found to possess potent antimicrobial activity. Unlike most mammalian cell membranes, bacterial membranes are rich in negatively-charged lipids such as cardiolipins and phosphatidylglycerol, which attract cationic amphiphiles through ionic interactions,[5] a fact that may be utilized for selective targeting of bacterial membranes.

In this manuscript we report the design, synthesis, and antibacterial activity of 18 cationic amphiphiles (**4a–r**) derived from tobramycin (TOB) (Scheme 1A), a clinically important AG antibiotic that is becoming increasingly compromised by bacterial resistance. We also provide evidence for the mode of action of these derivatives and for the structural requirements for bacterial membranes targeting compared to membranes of red blood cells (RBCs).

We chose to modify the 6"-primary alcohol of TOB and focused on two groups of lyophilic substituents: (i) aliphatic moieties including linear alkyl chains ranging from 6 to 22 carbons in length as well as branched and cyclic alkyls, and (ii) substituted aryl rings. The five amine groups of TOB were protected by Boc groups and the 6"-primary alcohol was selectively converted to the corresponding *O*-trisyl leaving group to provide compound **2** as previously reported (Scheme 1A).[7] Compound **2** was then reacted with each of the 18 aliphatic and

aromatic thiols resulting with the Boc-protected compounds **3a–r** in yields ranging from 57 to 94%. Removal of all Boc protecting groups in neat TFA gave the TFA salts of the 6"-thioether TOB derivatives **4a–r** with no need for further purification in yields ranging from 74 to 98%.

Compounds **4a–r** were screened for their antibacterial activity against 21 Gram-positive and Gram-negative bacterial strains and their minimum inhibitory concentrations (MICs) were determined (Table 1). Amongst the Gram-positive bacteria were pathogenic strains such as methicillin-resistant *Staphylococcus aureus* (MRSA) (strain **C**) and vancomycin-resistant *Enterococcus* (VRE) (strain **J**) that displayed high levels of resistance to TOB (MIC 150 μg/mL). Amongst the Gram-negative were 3 strains of *E. coli* BL21 (DE3) that we cloned with AMEs: the bi-functional AAC(6')/APH(2"), AAC(3)-IV, and the multi-acetylating Eis, an AAC that confers high levels of resistance to AGs in extensively-drug resistant (XDR) strains of *Mycobacterium tuberculosis* (*Mtb*)[8] (strains **O**, **P**, and **Q**, respectively). These three strains had significant to high levels of resistance to TOB (MICs >150, =150, and 18.8 μg/mL, respectively).

The linear aliphatic-chain analogues **4a–h** exhibited a parabolic pattern of chain-length dependent antibacterial activity (Figure S45A). Compared to TOB, both the C_6- and C_8-chain analogues **4a** and **4b** demonstrated a dramatic loss of antibacterial activity, the C_{10}-chain derivative **4c** regained some activity, and the C_{12}-chain analogue **4d** demonstrated potent antibacterial activity against several of the strains with resistance to TOB. The greatest improvement in antibacterial activity was observed for the C_{14}- and C_{16}-chain derivatives **4e** and **4f**, with the most significant effect for **4e** that showed marked activity against all of the 21 tested strains. The MIC values of **4e** ranged between 0.3 to 18.8 μg/mL against 19 of the 21 tested strains: the exceptions were *E. faecalis* (**K**) and *S. enterica* (**U**) where only a limited improvement in the antibacterial activity of **4e** as compared to TOB was observed (MIC of **4e**: 75 and 37.5 μg/mL, respectively, and for TOB: 150 μg/mL). The antibacterial activity dropped again for the C_{18}- and the C_{22}-chain analogues **4g** and **4h**. With few exceptions, a general drop in the antibacterial activity was observed for the 6"-aromatic-thioethers (**4k–r**). The more substitution around the aryl ring, the more significant was the loss of antibacterial activity against the tested strains. For example, of the aromatic thioether analogues, **4k** with the thiophenyl ring, and **4l** with the 4-methyl-thiophenyl ring, demonstrated the best overall antibacterial activity against the tested strains. However, a drop in antibacterial activity was observed for the 2,6-dimethyl-thiophenyl derivative **4m**, and a more significant drop was observed for the 2,4,6-trimethyl-thiophenyl analogue **4n**. Since thioethers may be susceptible to cellular mediated *S*-oxidation,[9] we oxidized two of the most potent thioethers (**4d–e**) to diastereomeric mixtures (~4:1 ratio) of the corresponding sulfoxides (**5d–e**) and to the sulfones (**6d–e**) (Scheme 1B). The effect of *S*-oxidation on the antibacterial activity varied amongst the tested bacterial strains. A reduction in the antibacterial activity of both sulfoxide and sulfone analogues as compared to the parent thioethers was observed for the *E. coli* BL21 (DE3) strains **M–Q** and for *B. subtilis* 168 with AAC(6')/APH(2")-pRB374 (strain **G**). In contrast, when tested against *E. faecalis* (**K**) and *L. monocytogenes* (**L**), all four *S*-oxidized analogues demonstrated improved antibacterial activities compared to that of the thioethers **4de**. For most of the tested strains, *S*-oxidation did not have a dramatic effect on the antibacterial activity with MIC values identical or one double-dilution higher than those of the thioethers **4d–e**. In most of the tested strains, MIC values were identical for the sulfoxides (**5d–e**) and the corresponding sulfones (**6d–e**) indicating that the level of *S*-oxidation has little to no effect on antibacterial activity.

To uncover the reasons for the broad spectrum and improved antimicrobial activity of some of the thioether analogues, we performed several biological tests. The effect of compound **4e**

on the translation of a luciferase reporter gene was measured in *E. coli* cell lysates. In lysates of *Mycobacterium smegmatis* and *E. coli*, previous studies reported that TOB inhibited luciferase translation at IC_{50} values of ~20 nM.[10] In our *E. coli* cell lysate, TOB potently inhibited translation ($IC_{50} = 8.9 \pm 1.9$ nM), whereas **4e** did not reach IC_{50} value even at 147 nM (measured using the free base forms of TOB and **4e**), suggesting that this compound does not target the bacterial ribosome as its major mode of antibacterial activity.

Furthermore, time of kill assays performed on *S. mutans* UA159 (**E**) and *S. pyogenes* (**D**) revealed that **4e** rapidly conferred bacterial cell death as compared to TOB (Figure S45B). At MIC values (2.3 μg/mL for **4e** on both strains, and 75 μg/mL (*S. mutans*) or 18.8 μg/mL (*S. pyogenes*) for TOB) no viable bacteria remained in the sample treated with **4e** after 5 hours of incubation with *S. mutans* and 3 hours of incubation with *S. pyogenes*. For both of these strains, almost no reduction in bacterial growth was observed for TOB after the same incubation time. The luciferase translation assay results and the rapid time of kill displayed by **4e** suggested that this compound acts by disrupting the bacterial cell membrane. Additional strong evidence for the membrane disruption effect of **4e** was obtained by fluorescence microscopy experiments (Figure 1). Fluorescently labeled *B. subtilis* with constitutive YFP expression (PY79)[11] was incubated for 1 hour with **4e** or with TOB at several concentrations. After 1 hour of incubation with TOB at both 2× and 8× the MIC (2.3 and 9.4 μg/mL, respectively), most of the bacterial cells in the sample were viable and maintained good fluorescence. In contrast, a significant drop in fluorescence presumably resulting from the bacterial cell lysis and loss of intracellular content including the YFP was evident after the same incubation time with compound **4e** at both 2× and 8× the MIC (4.7 and 18.8 μg/mL, respectively).

The selectivity of the 6"-thioether derivatives **4b–h** towards bacterial membranes was tested using a hemolysis assay on both laboratory rat and human RBCs (Figure 2). The MICs of the most potent thioether analogues ranged between 0.3 to 18.8 μg/mL. Hence, RBCs samples were incubated with analogues **4d–f** at a concentration of 75 μg/mL, which is 4–250 times greater than the MIC range and at 18.8 μg/mL, which is 1–60 times the MIC range. At 75 μg/mL, TOB as well as compounds **4b** and **4c** with the C_8- and C_{10}-linear chains caused no measurable hemolysis of rat and human RBCs. Compound **4d** with the C_{12}-chain caused $12.6 \pm 0.6\%$ hemolysis of rat RBCs and $7.9 \pm 1.7\%$ hemolysis of human RBCs. Both compounds **4e** (C_{14}-chain) and **4f** (C_{16}-chain) caused extensive hemolysis at 75 μg/mL with $93.6 \pm 5.5\%$ and $90.2 \pm 4.5\%$ of rat RBCs, and $93.7 \pm 11.1\%$ and $93.1 \pm 5.1\%$ of human RBCs, respectively. Compound **4g** (C_{18}-chain) caused $77.2 \pm 7.0\%$ hemolysis of rat RBCs and $74.3 \pm 9.0\%$ hemolysis of human RBCs. A significant drop in the hemolytic activity was observed for compound **4h** (C_{22}-chain), $24.4 \pm 5.8\%$ of rat RBCs and $7.1 \pm 0.1\%$ of human RBCs.

At 18.8 μg/mL, TOB and analogues **4b–d** with the C_8-, C_{10}-, and C_{12}-linear chains caused no measurable hemolysis of both rat and human RBCs, and compound **4e** (C_{14}-chain) caused $19.5 \pm 0.3\%$ hemolysis of rat RBCs and $14.3 \pm 1.7\%$ hemolysis of human RBCs. Compound **4f** (C_{16}-chain) demonstrated the maximal hemolytic effect of $40.4 \pm 1.7\%$ (rat RBCs) and $25.4 \pm 2.1\%$ (human RBCs), while **4g** (C_{18}-chain) caused $26.3 \pm 1.9\%$ hemolysis of rat RBCs and $8.0 \pm 0.8\%$ hemolysis of human RBCs. At 18.8 μg/mL compound **4h** (C_{22}-chain) caused $4.4 \pm 0.5\%$ hemolysis of rat RBCs and no measurable hemolysis of human RBCs. Although compound **4f** with the C_{16}-chain was one of the most active TOB analogues against the tested bacterial strains, it readily disrupted RBC membranes as well. In contrast, compound **4d** (C_{12}-chain) demonstrated potent antimicrobial activity against several of the TOB-resistant bacterial strains and caused little to no measurable hemolysis at the tested concentrations. The hemolysis assay demonstrated that the aliphatic chain length plays a key role in selective targeting of the bacterial membranes versus those of RBCs.

Several amphiphilic AGs based on paromomycin were recently shown to act as inhibitors of the AME APH(3').[12] Moreover, amphiphilic AGs can make their way into the bacterial cell where they are exposed to enzymatic modifications by AMEs. AME modifications (*O*-phosphorylation, *O*-adenylation, and *N*-acetylation), result in a reduction of the overall positive charge of the parent AG. Hence, AME modifications may reduce the affinity of amphiphilic AGs to the negatively-charged bacterial membrane and hamper their antimicrobial activity. Structural information obtained from crystallographic studies of several AMEs indicated that the AG binding pocket is rich in negatively-charged amino acid residues such as glutamic and aspartic acids and that several water molecules are required to stabilize the interactions between AGs and the AMEs' binding pockets.[13] We reasoned that the replacement of the 6"-primary alcohol of TOB with hydrophobic residues would interfere with these hydrophilic-based binding interactions and reduce the ability of the enzymes to modify these molecules. To test this hypothesis, the relative activities of seven different AMEs[14] on compounds **4a–r** were compared to that of TOB (Figure 3). While some of the modified compounds served as better substrates for some AMEs, in general a drop in the AME catalytic activity was observed in most of the cases. Analogues **4d–f**, which demonstrated the most potent antimicrobial activities, were also the poorest substrates for all of the tested AMEs.

Hence, bacterial strains containing the tested AMEs will have limited to no ability to inactivate analogues **4d–f** through chemical modifications that are catalyzed by these enzymes. This is also true for the *S*-oxidized compounds **5d–e** and **6d–e**, which behaved similarly to their non-oxidized counterparts **4d–e** (Figure S46).

In conclusion, 18 novel 6"-thioether TOB analogues (**4a–r**) and 4 *S*-oxidized compounds (**5d–e** and **6d–e**) have been synthesized and screened for antibacterial activity. The C_{12}-, C_{14}-, and C_{16}-linear chain analogues **4d–f** demonstrated potent activity against bacterial strains with high levels of resistance to TOB. We found evidence that the most potent analogue **4e** targets bacterial membranes and no longer targets the ribosome as does the parent drug. Hemolysis tests indicated that it is possible to improve the antibacterial activity while reducing the undesired hemolytic effect by altering the length of the aliphatic chain. Finally, thioethers **4d–f** served as poor substrates for several AMEs, demonstrating that AMEs have a limited deactivating effect on these AG analogues. The results reported in this manuscript offer guidelines for the design of bacterial membrane targeting amphiphilic AGs.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

References

[1]. a) Fridman M, Belakhov V, Yaron S, Baasov T. Org. Lett. 2003; 5:3575–3578. [PubMed: 14507176] b) Houghton JL, Green KD, Chen W, Garneau-Tsodikova S. Chembiochem. 2010; 11:880–902. [PubMed: 20397253] c) Wright GD, Berghuis AM, Mobashery S. Adv. Exp. Med. Biol. 1998; 456:27–69. [PubMed: 10549363]

[2]. a) Magnet S, Blanchard JS. Chem. Rev. 2005; 105:477–498. [PubMed: 15700953] b) Mingeot-Leclercq MP, Glupczynski Y, Tulkens PM. Antimicrob. Agents Chemother. 1999; 43:727–737. [PubMed: 10103173]

[3]. Kotra LP, Haddad J, Mobashery S. Antimicrob. Agents Chemother. 2000; 44:3249–3256. [PubMed: 11083623]

[4]. a) Ouberai M, El Garch F, Bussiere A, Riou M, Alsteens D, Lins L, Baussanne I, Dufrene YF, Brasseur R, Decout JL, Mingeot-Leclercq MP. Biochim. Biophys. Acta. 2011; 1808:1716–1727. [PubMed: 21291859] b) Bera S, Zhanel GG, Schweizer F. J. Med. Chem. 2010; 53:3626–3631. [PubMed: 20373816] c) Baussanne I, Bussiere A, Halder S, Ganem-Elbaz C, Ouberai M, Riou

M, Paris JM, Ennifar E, Mingeot-Leclercq MP, Decout JL. J. Med. Chem. 2010; 53:119–127. [PubMed: 20000576] d) Hanessian S, Pachamuthu K, Szychowski J, Giguere A, Swayze EE, Migawa MT, Francois B, Kondo J, Westhof E. Bioorg. Med. Chem. Lett. 2010; 20:7097–7101. [PubMed: 20970332]

[5]. Epand RF, Savage PB, Epand RM. Biochim. Biophys. Acta. 2007; 1768:2500–2509. [PubMed: 17599802]

[6]. a) Findlay B, Zhanel GG, Schweizer F. Antimicrob. Agents Chemother. 2010; 54:4049–4058. [PubMed: 20696877] b) Giuliani A, Rinaldi AC. Cellular and molecular life sciences. 2011; 68:2255–2266. [PubMed: 21598022] c) Yin LM, Edwards MA, Li J, Yip CM, Deber CM. J. Biol. Chem. 2012; 287:7738–7745. [PubMed: 22253439]

[7]. a) Wang H, Tor Y. Bioorg. Med. Chem. Lett. 1998; 8:3665–3670. [PubMed: 9934492] b) Wang H, Tor Y. Angew. Chem. Int. Ed. Engl. 1998; 37:109–111.

[8]. a) Chen W, Biswas T, Porter VR, Tsodikov OV, Garneau-Tsodikova S. Proc. Natl. Acad. Sci. U S A. 2011; 108:9804–9808. [PubMed: 21628583] b) Green KD, Chen W, Garneau-Tsodikova S. ChemMedChem. 2012; 7:73–77. [PubMed: 21898832]

[9]. a) Wynalda MA, Hutzler JM, Koets MD, Podoll T, Wienkers LC. Drug. Metab. Dispos. 2003; 31:878–887. [PubMed: 12814964] b) Katopodis AG, Smith HA, May SW. J. Am. Chem. Soc. 1988; 110:897–899.

[10]. a) Hobbie SN, Kalapala SK, Akshay S, Bruell C, Schmidt S, Dabow S, Vasella A, Sander P, Bottger EC. Nucleic Acids Res. 2007; 35:6086–6093. [PubMed: 17766247] b) Sucheck SJ, Wong AL, Koeller KM, Boehr DD, Draker K-A, Sears P, Wright GD, Wong C-H. J. Am. Chem. Soc. 2000; 122:5230–5231.

[11]. Eldar A, Chary VK, Xenopoulos P, Fontes ME, Loson OC, Dworkin J, Piggot PJ, Elowitz MB. Nature. 2009; 460:510–514. [PubMed: 19578359]

[12]. Szychowski J, Kondo J, Zahr O, Auclair K, Westhof E, Hanessian S, Keillor JW. ChemMedChem. 2011; 6:1961–1966. [PubMed: 21905229]

[13]. a) Wolf E, Vassilev A, Makino Y, Sali A, Nakatani Y, Burley SK. Cell. 1998; 94:439–449. [PubMed: 9727487] b) Wybenga-Groot LE, Draker K, Wright GD, Berghuis AM. Structure. 1999; 7:497–507. [PubMed: 10378269] c) Sakon J, Liao HH, Kanikula AM, Benning MM, Rayment I, Holden HM. Biochemistry. 1993; 32:11977–11984. [PubMed: 8218273] d) Hon WC, McKay GA, Thompson PR, Sweet RM, Yang DS, Wright GD, Berghuis AM. Cell. 1997; 89:887–895. [PubMed: 9200607]

[14]. a) Green KD, Chen W, Garneau-Tsodikova S. Antimicrob. Agents Chemother. 2011; 55:3207–3213. [PubMed: 21537023] b) Porter VR, Green KD, Zolova OE, Houghton JL, Garneau-Tsodikova S. Biochem. Biophys. Re.s Commun. 2010; 403:85–90.

Figure 1.
Bright field and epi-fluorescence microscopy. *B. subtilis* (PY79) cells carrying YFP under an inducible IPTG promoter treated with TOB at 2.3 µg/mL (2× MIC) and 9.4 µg/mL (8× MIC) or with compound **4e** at 4.7 µg/mL (2× MIC) and 18.8 µg/mL (8× MIC).

Figure 2.
Hemolysis tests. Human RBCs (blue "18.8 µg/mL" and green "75 µg/mL") and rat RBCs (red "18.8 µg/mL" and orange "75 µg/mL") were incubated with TOB or with analogues **4b–h** at concentrations of 18.8 µg/mL or 75 µg/mL for 1 h at 37 °C.

Figure 3.
Bar graph showing the relative initial rates of AME reactions with TOB and the 6"-thioether analogues **4a–r**. Rates are normalized to TOB. AMEs tested include AAC(6')-IId (blue), AAC(6')-Ib (cyan), AAC(6')/APH(2") (dark green), Eis (light green), AAC(3)-IV (yellow), AAC(2')-Ic (orange), and ANT(4') (red).

Scheme 1.
A. Synthesis of 18 novel 6"-thioether TOB derivatives (**4a–r**). **B.** Oxidation of the thioether analogues **3d–e** into the corresponding sulfoxides **5d–e** and sulfones **6d–e**.

Table 1

Antibacterial activity: MIC values (µg/mL) of the 6''-thioether TOB derivatives **4a–r**, **5d–e**, and **6d–e** compared to the parent drug TOB.

AG	Gram-positive bacterial strains[a]												Gram-negative bacterial strains[b]								
	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P	Q	R	S	T	U
TOB	0.3	9.4	>150	18.8	75	1.2	9.4	18.8	2.3	>150	150	4.7	4.7	9.4	>150	150	18.8	4.7	9.4	18.8	150
4a	75	>150	>150	>150	>150	150	>150	>150	150	>150	>150	75	>150	>150	>150	>150	>150	18.8	150	>150	>150
4b	75	150	>150	150	150	37.5	>150	150	75	>150	>150	>150	>150	>150	>150	>150	>150	9.4	75	>150	>150
4c	9.4	37.5	75	150	9.4	37.5	>150	18.8	4.7	>150	>150	37.5	75	>150	>150	150	>150	2.3	9.4	>150	>150
4d	2.3	9.4	37.5	9.4	4.7	4.7	>150	4.7	9.4	>150	150	18.8	18.8	>150	>150	150	150	4.7	18.8	37.5	150
4e	1.2	9.4	9.4	2.3	2.3	1.2	4.7	1.2	0.3	18.8	75	9.4	4.7	4.7	4.7	2.3	4.7	4.7	4.7	18.8	37.5
4f	4.7	4.7	9.4	9.4	9.4	4.7	18.8	2.3	1.2	18.8	18.8	4.7	18.8	4.7	4.7	4.7	18.8	4.7	4.7	37.5	>150
4g	9.4	>150	18.8	>150	>150	75	>150	>150	9.4	>150	150	75	>150	>150	>150	>150	>150	4.7	>150	>150	>150
4h	75	>150	>150	>150	>150	150	>150	>150	18.8	>150	>150	18.8	>150	>150	>150	>150	>150	>150	>150	>150	>150
4i	1.2	150	>150	75	75	75	>150	>150	75	>150	150	2.3	18.8	>150	>150	>150	150	18.8	9.4	150	>150
4J	4.7	18.8	>150	37.5	>150	9.4	150	150	18.8	>150	150	4.7	75	>150	>150	>150	75	9.4	18.8	>150	>150
4k	2.3	9.4	>150	18.8	>150	9.4	18.8	>150	9.4	>150	75	4.7	9.4	37.5	>150	>150	75	2.3	4.7	37.5	>150
4l	4.7	9.4	>150	18.8	>150	4.7	9.4	150	9.4	>150	75	4.7	18.8	37.5	150	>150	37.5	1.2	2.3	37.5	>150
4m	18.8	75	150	>150	150	37.5	150	37.5	37.5	>150	150	9.4	75	150	>150	>150	150	4.7	18.8	>150	>150
4n	75	150	>150	150	150	18.8	>150	75	18.8	>150	>150	37.5	150	>150	>150	>150	>150	9.4	150	>150	>150
4o	75	>150	>150	150	150	>150	>150	>150	150	>150	>150	>150	>150	>150	>150	>150	>150	18.8	150	>150	>150
4p	9.4	>150	>150	150	75	18.8	150	75	37.5	>150	>150	37.5	150	>150	150	>150	>150	9.4	37.5	>150	>150
4q	18.8	37.5	>150	150	150	37.5	150	>150	37.5	>150	>150	37.5	75	150	>150	>150	>150	9.4	9.4	150	>150
4r	37.5	>150	>150	>150	>150	>150	>150	>150	>150	>150	150	150	>150	>150	>150	>150	>150	75	150	150	>150
5d	4.7	37.5	75	18.8	9.4	4.7	>150	9.4	2.3	150	18.8	9.4	75	>150	>150	37.5	>150	2.3	18.8	150	>150
5e	2.3	18.8	18.8	4.7	2.3	1.2	75	1.2	0.3	37.5	9.4	2.3	37.5	75	37.5	37.5	75	4.7	9.4	37.5	75
6d	9.4	37.5	75	18.8	9.4	4.7	>150	9.4	2.3	75	9.4	9.4	75	>150	>150	>150	>150	2.3	18.8	>150	>150
6e	2.3	18.8	18.8	4.7	4.7	1.2	37.5	1.2	0.3	37.5	4.7	2.3	18.8	75	37.5	75	75	2.3	9.4	37.5	75

[a] *S. epidermidis* AJCCM228 (**A**), *S. aureus* NorA (**B**), MRSA (**C**), *S. pyogenes* serotype M12 (strain MGAS9429) (**D**), *S. mutans* UA159 (**E**), *B. subtilis* 168 (**F**), *B. subtilis* 168 with AAC(6')/APH(2'')-pRB374 (**G**), *B. cereus* ATCC11778 (**H**), *B. anthracis* 34F2 Sterne strain (**I**), VRE (**J**), *E. faecalis* ATCC29212 (**K**), and *L. monocytogenes* ATCC19115 (**L**).

[b] *E. coli* BL21 (DE3) (**M**), *E. coli* BL21 (DE3) with pET22b (**N**), *E. coli* BL21 (DE3) with AAC(6')/APH(2'')-pET22b (**O**), *E. coli* BL21 (DE3) with AAC(3)-IV-Int-pET19b-pps (**P**), *E. coli* BL21 (DE3) with pET22b (**Q**), *E. coli* TolC (**R**), *E. coli* MC1061 (**S**), *Shigella* clinical isolate 6831 (**T**), and *S. enterica* ATCC14028 (**U**).